In cancer cells, the two isozymes serve contrasting functions in tumorigenesis; GLS1 is associated with tumor growth and malignant transformation modified by the cancer-associated protein c-Myc, whereas GLS2's ability is tumor suppression, which is manipulated by p53 [22–24]. This evidence concerns the gene GLS2 and cancer.